EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes

Lingfeng Chen, Zhijie You, Xunbin Yu, Yijuan Wu, Xin Chen, Jie Lin

Pathology & Oncology Research · 28.07.2026 · 32

DOI: 10.3389/pore.2026.1612465 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology & Oncology Research, online erschienen am 28.07.2026. Verfasst von Lingfeng Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Prov…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, High-Throughput Nucleotide Sequencing, Biomarkers, Tumor, Mutation. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to evaluate the efficacy of a single-test, targeted DNA next-generation sequencing (NGS) panel in classifying endometrial carcinoma (EC) into molecular subtypes and to compare its performance with that of the established Sanger sequencing + immunohistochemistry (Sanger + IHC) molecular classification.

Methods

Targeted DNA NGS was performed on 131 samples using the clinically validated AmoyDx® Comprehensive Panel, and a commercially available targeted AmoyDx EC Panel covering POLE, TP53, and MSI was used for 63 samples.

Results

The concordance between the NGS and Sanger + IHC classifications was 93.8% (182/194 cases), with a kappa value of 0.908. The exclusion of seven discordant POLE mutations improved concordance to 97.4% (kappa = 0.962). NGS identified 30 POLE mutations compared to 23 detected by Sanger sequencing, which missed low-frequency variants. Microsatellite instability (MSI) analysis and mismatch repair (MMR) immunohistochemistry (IHC) results were highly concordant (97.9%). However, NGS-based TP53 mutation detection showed moderate agreement with the p53 IHC results (kappa = 0.688). Mutations associated with targeted therapy trials, including PTEN (76.3%), PIK3CA (50.4%), and ARID1A (35.9%), were found in 131 EC samples.

Conclusion

These findings indicate that NGS-based molecular classification aligns well with Sanger + IHC molecular classification and offers higher sensitivity than Sanger sequencing, thereby improving the identification of mutations associated with targeted therapy trials. This enhances the prognosis and treatment planning for patients with advanced EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsHigh-Throughput Nucleotide SequencingBiomarkers, TumorMutationHumansFemaleMiddle AgedMicrosatellite InstabilityAgedImmunohistochemistryTumor Suppressor Protein p53PrognosisAdultAged, 80 and over

Stichwörter der Autor:innen

NGSSanger sequencingendometrial carcinomaimmunohistochemistrymolecular classification

Substanzen

Biomarkers, TumorTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.

Zitieren

APA

Chen, L., You, Z., Yu, X., Wu, Y., Chen, X., & Lin, J. (2026). Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes. Pathology & Oncology Research, 32. https://doi.org/10.3389/pore.2026.1612465

Vancouver

Chen L, You Z, Yu X, Wu Y, Chen X, Lin J. Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes. Pathology & Oncology Research. 2026;32. doi:10.3389/pore.2026.1612465

BibTeX
@article{Chen2026,
  author = {Chen, Lingfeng and You, Zhijie and Yu, Xunbin and Wu, Yijuan and Chen, Xin and Lin, Jie},
  title = {Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes},
  journal = {Pathology & Oncology Research},
  year = {2026},
  volume = {32},
  doi = {10.3389/pore.2026.1612465}
}
Kostenlos starten →